Compare DLO & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | RLAY |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.1B |
| IPO Year | 2021 | 2020 |
| Metric | DLO | RLAY |
|---|---|---|
| Price | $13.60 | $17.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $17.25 | ★ $19.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.9M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $26.98 | $324.03 |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $10.64 | $5.17 |
| 52 Week High | $16.78 | $21.27 |
| Indicator | DLO | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 43.01 |
| Support Level | $13.14 | $11.68 |
| Resistance Level | $15.55 | $20.29 |
| Average True Range (ATR) | 0.37 | 0.83 |
| MACD | -0.11 | -0.11 |
| Stochastic Oscillator | 0.00 | 34.28 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.